Iovance Biotherapeautics

Q3 FY2026 EarningsQ3 FY26 results significantly beat consensus across all key financial metrics, driven by accelerated commercial momentum for Amtagvi and strong Proleukin performance. Revenue of $121.5M exceeded the $115.6M expectation by 5.11%, while gross margin reached 60.46%, a 3.20pct beat against the 57.26% forecast. Continued operational streamlining and reduced R&D expenses narrowed operating losses to $24.0M, far superior to the -$41.0M consensus loss, resulting in a GAAP EPS beat of $0.04.